Slide 1 Relationship of Drug Associated Change in Bone Mineral Density to Fracture Risk Marc C. Hochberg, MD, MPH FDA Endocrinologic and Metabolic Drugs Advisory Committee…
Learning Objectives After attending this symposium, participants will be able to: Explain the heterogeneity of bone fragility in terms of pathogenesis and structural properties…
Osteoporosis Internal Medicine Lecture Series Danielle Hansen DO, MS September 26, 2007 Definition Skeletal Disorder Characterized by Compromised Bone Strength Predisposing…